The INFORM2-NivEnt trial is positioned to explore the efficacy of a novel combination therapy in a pediatric population with high-risk malignancies, a segment with significant unmet medical needs. The trial's focus on specific biomarkers (high mutational load, MYC(N) amplification, high TILs, and TLS) may provide a competitive edge in precision medicine, potentially leading to a differentiated therapeutic profile. Given the limited treatment options for refractory pediatric cancers, successful outcomes could facilitate market entry and establish a strong foothold in a niche yet critical market. The collaboration with University Hospital Heidelberg and the German Cancer Research Center enhances credibility and may attract further investment or partnerships.